Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch & Poster Display session

85P - Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC)

Date

12 Dec 2019

Session

Lunch & Poster Display session

Presenters

Oliver Schmalz

Citation

Annals of Oncology (2019) 30 (suppl_11): xi16-xi32. 10.1093/annonc/mdz449

Authors

O.O. Schmalz1, C. Jacob2, J. Ammann3, B. Liss1, S. Iivanainen4, M. Kammermann3, J. Koivunen4, M. Giger5, A. Klein3, R.A. Popescu6

Author affiliations

  • 1 Department Of Haematology, Oncology And Palliative Care, Helios Universitätsklinikum Wuppertal, 42283 - Wuppertal/DE
  • 2 The Faculty Of Business And Law, Lord Ashcroft International Business School, Anglia Ruskin University, Cambridge, United Kingdom And, School of Business, University of Applied Sciences Northwestern Switzerland, Brugg/CH
  • 3 Medical Affairs (personalised Healthcare And Patient Access), F. Hoffmann-La Roche Ltd, Basel/CH
  • 4 Department Of Oncology And Radiotherapy, Oulu University Hospital, Oulu/FI
  • 5 Department Of Medical Oncology And Hematology, Kantonsspital St. Gallen, St. Gallen and Rorschach/CH
  • 6 Tumor Zentrum Aarau, Hirslanden Klinik Aarau, Aarau/CH
More

Resources

Abstract 85P

Background

Pts with cancer have disease- and treatment-related symptoms. DPM can facilitate outpatient symptom detection and improve clinical practice, pt quality of life and health benefits. We assessed pt/healthcare professional (HCP) adoption and clinical impact of a DPM tool in CIT-treated pts with a/mNSCLC.

Methods

Literature research and pt/HCP advisory boards identified factors influencing DPM use and CIT-related symptoms. These were used to develop a drug-/indication-specific CIT pt module for the Kaiku Health DPM platform, encompassing a symptom questionnaire (per National Cancer Institute Common Terminology Criteria for Adverse Events), HCP symptom overview/alerts, direct pt–HCP communication and pt education for mild/moderate symptoms. The DPM tool was tested over 3 months in Switzerland, Finland and Germany (10 clinics; 45 pts; 2L+ CIT monotherapy). User experience, overall satisfaction and clinical practice impact data from an online survey/HCP interviews were analysed quantitatively/qualitatively.

Results

Of the 21 pt/27 HCP online survey respondents, 73% rated themselves as competent/proficient/expert and 85% used the tool at least weekly; 60% for ≤ 10 min per week (pts)/day (HCPs). Most agreed that the tool facilitated more focused and efficient communication. Preferred functions by pts and HCPs were drug-specific information and symptom alerts, respectively. The table shows time needed for pt tool introduction and HCP time saved per pt visit. Telephone consultation need decreased for 33% of pts. Continuous monitoring led to earlier CIT symptom management in several pts. Tool expectations were met/exceeded for 89% of HCPs.

Table: 85P

HCPs, n (%) n = 27
Time for pt tool introduction
0 min (none done)7 (26)
< 30 min18 (67)
30–60 min2 (7)
> 60 min0
HCP time saved per pt visit
≤ 5 min6 (22)
6–10 min5 (19)
11–15 min1 (4)
No time saved7 (26)
More time spent1 (4)
Unsure7 (26)

Conclusion

The DPM tool educated and empowered pts and saved time on symptom reporting. It also improved care quality, efficiency and pt–HCP communication and enabled earlier symptom management, highlighting the contributions of DPM to clinical care.

Clinical trial identification

Editorial acknowledgement

Support for third-party writing assistance for this abstract, furnished by Katie Wilson, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Funding

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Disclosure

O.O. Schmalz: Advisory / Consultancy, Payment planned: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. C. Jacob: Advisory / Consultancy, External consultant to lead the study design, data analysis, and reporting: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. J. Ammann: Shareholder / Stockholder / Stock options, Full / Part-time employment: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. B. Liss: Advisory / Consultancy, Payment planned: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. S. Iivanainen: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses, Lecture: Boehringer Ingelheim; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Kaiku Health; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. M. Kammermann: Full / Part-time employment, Part-time contractor: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. J. Koivunen: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Takeda; Advisory / Consultancy, Travel / Accommodation / Expenses: Faron; Advisory / Consultancy, Travel / Accommodation / Expenses: Kaiku Health; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. M. Giger: Honoraria (self): F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. A. Klein: Shareholder / Stockholder / Stock options, Full / Part-time employment: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche. R.A. Popescu: Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Merck; Advisory / Consultancy: Lilly; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Vifor Pharma; Advisory / Consultancy: Nutricia; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): AbbVie; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings